Intervention

SGLT2 inhibitors (Dapagliflozin and Empagliflozin)

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions5

Lead sponsors shown2

Clinical trials

2 shown

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEFNCT07776054 · 2024-02-01

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure PatientsNCT06201000 · 2023-12-27

Common conditions

Atrial Fibrillation1 DC Cardioversion1 Genetic Polymorphisms1 Heart Failure1 SGLT2 Inhibitor1

Leading sponsors

October 6 University1 Samsung Medical Center1

Trial status mix

RECRUITING1

UNKNOWN1

Phase mix

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.